

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claim 1. (Withdrawn) An agent for the prevention and/or treatment of Alzheimer's disease containing c-Abl and/or p19^{ARF} as (an) active ingredient(s).

Claim 2. (Cancelled)

Claim 3. (Currently Amended) A screening method wherein a ~~candidate~~ drug which inhibits the interaction between AICD (APP intracellular C-terminal domains) and p53 in neurons is selected ~~[[as]]~~ for development of a drug for the prevention and/or treatment of Alzheimer's disease, said screening method comprising:

expressing AICD and p53 in the presence of cisplatin to form an AICD/p53 complex in neurons;

~~a step of culturing the neurons expressing AICD and p53 in which an AICD/p53 complex is formed,~~ together with a candidate drug;

homogenizing the cultured neurons to form a cell lysate;

~~a step of obtaining~~ bringing the cell lysate in contact with a first antibody selected from an anti-AICD antibody and an anti-p53 antibody, to form, to form a first immune complex ~~which is a complex of AICD or p53 with [[a]] the first antibody selected from an anti-AICD antibody and an anti-p53 antibody, and to form~~ a second immune complex ~~which is a complex of the AICD/p53 complex with the first antibody, by bringing a cell lysate prepared from the cultured neurons in contact with the first antibody;~~

Application No. 10/570,346
AMENDMENT dated May 12, 2008
Reply to Office Action of February 11, 2008

~~a step of bringing the first and second immune complexes in contact with a second antibody which is selected from an anti-AICD antibody and an anti-p53 antibody[[,]] and which is different from the first antibody, to form a third immune complex of the second immune complex with the second antibody; [[and]]~~

~~a step of detecting and quantifying the presence of a third immune complex which is a complex of the second immune complex with the second antibody using an immunological technique; and~~

~~selecting the candidate drug for development of a drug for the prevention and/or treatment of Alzheimer's disease,~~

~~wherein the candidate drug is selected, if the quantity of the third immune complex is small compared to the case where the candidate drug is not contained in the culture.~~

Claim 4. (Withdrawn) An agent for the prevention and/or treatment of Alzheimer's disease containing A1cICD as an active ingredient.

Claim 5. (Withdrawn) An agent for the prevention and/or treatment of Alzheimer's disease containing a peptide which comprises the amino acid sequence set forth in SEQ ID NO: 1 or 2 of the Sequence Listing as an active ingredient.

Claim 6. (Withdrawn) A screening method wherein a candidate drug which inhibits the interaction between AICD and Fe65 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease.

Claim 7. (Withdrawn) A screening method wherein a candidate drug which inhibits the interaction between AICD and Fe65 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease, said screening method comprising:

a step of culturing neurons expressing AICD and Fe65 in which an AICD/Fe65 complex is formed, together with a candidate drug;

a step of obtaining a first immune complex which is a complex of AICD or Fe65 with a first antibody selected from an anti-AICD antibody and an anti-Fe65 antibody, and a second immune complex which is a complex of the AICD/Fe65 complex with the first antibody, by bringing a cell lysate prepared from the cultured neurons in contact with the first antibody;

a step of bringing the first and second immune complexes in contact with a second antibody which is selected from an anti-AICD antibody and an anti-Fe65 antibody, and which is different from the first antibody; and

a step of detecting the presence of a third immune complex which is a complex of the second immune complex with the second antibody.

Claim 8. (Withdrawn) A screening method wherein a candidate drug which inhibits the interaction between AICD and Tip60 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease.

Claim 9. (Withdrawn) A screening method wherein a candidate drug which inhibits the interaction between AICD and Tip60 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease, said screening method comprising:

a step of culturing neurons expressing AICD and Tip60 in which an AICD/Tip60 complex is formed, together with a candidate drug;

a step of obtaining a first immune complex which is a complex of AICD or Tip60 with a first antibody selected from an anti-AICD antibody and an anti-Tip60 antibody, and a second immune complex which is a complex of the AICD/Tip60 complex with the first antibody, by bringing a cell lysate prepared from the cultured neurons in contact with the first antibody;

Application No. 10/570,346
AMENDMENT dated May 12, 2008
Reply to Office Action of February 11, 2008

a step of bringing the first and second immune complexes in contact with a second antibody which is selected from an anti-AICD antibody and an anti-Tip60 antibody, and which is different from the first antibody; and

a step of detecting the presence of a third immune complex which is a complex of the second immune complex with the second antibody.

Claim 10. (Withdrawn) A drug for the prevention and/or treatment of Alzheimer's disease which can be obtained by the screening method according to claim 3.

Claim 11. (Withdrawn) A drug for the prevention and/or treatment of Alzheimer's disease which can be obtained by the screening method according to claim 7.

Claim 12. (Withdrawn) A drug for the prevention and/or treatment of Alzheimer's disease which can be obtained by the screening method according to claim 9.